Kornimate/medical-research-clean huggingface dataset:
study of hydration levels in sports and non-sports schoolchildren (ehc)

Conditions: Hydration

Summary: new knowledge regarding the negative impact of poor hydration on health highlights the need to provide recent epidemiological data on the water intake of the french population, especially among middle school students, a group that has been minimally studied until now. given the crucial role of adequate hydration in sports performance, it is essential to assess fluid intake and hydration habits among middle school students, who often engage in intense physical activities. the primary outcome of this study is to evaluate whether the proportion of middle school students hydrating adequately according to current recommendations is higher among those engaging in moderate to intense sports compared to those who do little or no sports. the goal is to determine if daily fluid intake is significantly influenced by physical activity among this population. to achieve this, investigators have developed a questionnaire to gather information on the physical activity levels of middle school students, their daily hydration habits, and their liquid intake in relation to their sports activities, using appropriate visuals. this study involves distributing the questionnaire in two middle schools in brittany between november 2023 and january 2024.


Eligibility criteria:
inclusion criteria: * middle school students with little or no sports involvement and middle school students with a moderate to intense level of physical activity exclusion criteria: * refusal of the middle school student to participate and parental opposition to their child's participation in this research

Keywords: water beverage sports children middle school students adolescents dehydration
ventfirst: a multicenter rct of assisted ventilation during delayed cord clamping for extremely preterm infants

Conditions: Intraventricular Hemorrhage

Summary: the purpose of this study is to determine whether providing ventilatory assistance prior to umbilical cord clamping influences the occurrence of intraventricular hemorrhage (ivh) in extremely preterm (ept) infants, compared to standard care of providing ventilatory assistance after cord clamping.

newborns with gestational age 23 wks 0 days through 28 wks 6 days are randomized to control (delayed cord clamping for at least 30 seconds, or up to 60 seconds if breathing spontaneously, with ventilatory assistance provided after) or the ventfirst intervention (ventilatory assistance with continuous positive airway pressure or positive pressure ventilation given starting 30 seconds after birth and cord clamping at 120 seconds). the primary outcome is lack of ivh on 7-10 day head ultrasound or death before day 7. the study was designed to test the impact of the intervention in each of two cohorts: 1. infants not breathing well 30 seconds after birth 2. infants breathing well 30 seconds after birth randomization and analysis is stratified by gestational age category: 1. 23 0/6 to 25 6/7 weeks' gestation 2. 26 0/7 to 28 6/7 weeks' gestation

Eligibility criteria:
inclusion criteria: * 23 0/7 - 28 6/7 weeks' gestation at delivery exclusion criteria: * life-threatening condition of fetus (e.g. severe hydrops, lethal chromosomal abnormality, severe congenital malformation) * suspected severe fetal anemia * monochorionic or monoamniotic twins * multiple gestation greater than twins * decision made for comfort care only * medical emergency necessitating emergency delivery (e.g. complete placental abruption) * obstetrician or neonatology concern for inappropriateness of the study intervention based on maternal or fetal factors.

Keywords: umbilical cord clamping intraventricular hemorrhage extremely preterm infants
a treatment access program to provide maraviroc to eligible adult patients completing a4001050 study until commercial availability of maraviroc (celsentri) in india

Conditions: Human Immunodeficiency Virus (HIV)

Summary: the new protocol will allow the patients enrolled on a4001050 to have continuous access of maraviroc and the treatment will not be interrupted until the drug is commercially available in india.


Eligibility criteria:
inclusion criteria: * subjects who complete the a4001050 study and are continuing to derive benefit from maraviroc. * subjects who are willing and able to comply with scheduled visits, treatment plan and other study procedures. exclusion criteria: * subjects who discontinued in a4001050 study. * unable to provide consent.

Keywords: open label access program treatment experienced
ischemic conditioning of the gastric conduit in esophageal cancer.

Conditions: Esophageal Anastomotic Leak; Tissue Pressure of Oxygen

Summary: this study is a randomized clinical trial to clarify if preoperative embolization of gastric arteries can reduce the incidence of oesophagogastric leakage after an esophagectomy for esophageal cancer comparing an experimental group vs control group.

in patients with infracarinal esophageal carcinoma, the surgery is a complex procedure and with a high morbidity. it consists of a subtotal esophagectomy with tubular gastroplasty and cervical esophagogastric anastomosis. the most important complication is the anastomotic leakage with a high mortality. among the possible causes of anastomotic leakage an important factor is the impaired microcirculation in the anastomotic region after the partial devascularization of the stomach during the surgery. there are several experimental studies about the different techniques to improve this vascularization and their effects on mucosal oxygenation. there are several methods currently used for assessing tissue oxygenation. the polarographic partial pressure of oxygen (po2) electrode has been considered as the 'gold standard' for measuring oxygen tension. this is the reason why tissue pressure of oxygen (ptio2) will be measured by licox® (integra neuroscience) system in two groups. there aren't prospective randomized controlled trials to answer these questions. for this reason the investigators propose to perform a prospective randomized controlled trial in patients underwent on this surgery, comparing two groups: one of them will be carried out a preoperative arterial embolization (pae), and the other one will be operated directly, to demonstrate if the ischemic conditioning by pae can reduce the incidence of anastomotic esophagogastric leakage and improve the gastric conduit oxygenation.

Eligibility criteria:
inclusion criteria: * all patients requiring a esophagectomy with cervical esophagogastrostomy for esophageal cancer * 18 or above years old * karnofsky\>50% * acceptance and signing the full informed consent exclusion criteria: * fistula tracheobronchial * metastatic disease * anatomic vascular alteration that contraindicate the embolization (congenital celiac trunk stenosis, presence of arcuate ligament, atherosclerotic stenosis, etc,..) * severe cardiorespiratory failure * refuse to collaborate in the study
the effect of running water sound listened to patients during hemodialysis

Conditions: Hemodialysis Patients

Summary: it is known that being in nature and the visual perception of nature positively affects an individual's mood and self-confidence. studies have reported that natural sounds have a positive effect in situations such as pain, anxiety, and stress. this finding means that listening to natural sounds may be a simple and easily accessible intervention that can positively impact key human stress systems. although many non-pharmacological methods are used in the literature to reduce the invasive pain and anxiety experienced by hemodialysis (hd) patients during cannulation, the most popular recently; however, we aimed to determine the effect of the sound of running water, which we have not yet encountered in dialysis patients, on invasive pain and anxiety experienced during fistula access.

in this study; between 15 december 2023 and 15 march 2024, patients receiving dialysis will be included in the dialysis service of two hospitals in western of turkey which havedialysis for 3 days a week. the sample calculation was determined using power analysis based on a previous study. (çetinkaya, karabulut (2010). the sample size of the study was calculated as at least 30 patients, for each group that met the sampling criteria. the population of the research was determined as 74 people. the number of patients who met the inclusion criteria was 68, and these patients were assigned to the experimental (34 patients) and control (34 patients) groups by an independent statistician with the help of a computer program (randomizer.org). patients over the age of 18, who are volunteers, who undergo dialysis 3 days a week, who do not have any communication problems and who do not use any psychiatric medication will be included in the study. patients who do not meet the inclusion criteria will be excluded from the study. dialysis sessions are held 3 days a week, between 08.00-16.00, on mon-wed-fri and tuesday-thurs-sat. all patients who volunteer to participate in the study will be included in the study. during the cannulation process, the experimental group will listen to the sound of flowing water throughout the process with the help of the researcher's smartphone. vas scale will be applied to the experimental and control groups after each cannulation, and the state and trait anxiety scale will be applied before the first dialysis session and after the 12th session. the control group will receive standard care. a total of 12 sessions will be followed in both groups.

Eligibility criteria:
inclusion criteria: * between 18 - 65 years * not have communication problem * patients receiving dialysis 3 days a week * have cannulation exclusion criteria: * under 18- over 65 years * have communication problems * not have dialysis 3 days a week * have not cannulation

Keywords: anxiety pain
the elutes clinical trial

Conditions: Coronary Artery Disease

Summary: elutes is a european multicenter, randomized, controlled, triple-blinded study designed to evaluate the ability of the paclitaxel eluting v-flex plus coronary stent to reduce restenosis in the coronary artery.


Eligibility criteria:
inclusion criteria: * patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery. * patient must be an acceptable candidate for coronary artery bypass surgery. * patient or legal guardian must have signed informed consent. * patient agrees to return at one month for an office visit to assess cardiovascular status and at 6 months for an office visit to assess cardiovascular status and for a diagnostic angiogram. exclusion criteria: * patient must be less than 18 years old. * patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions. * patient is simultaneously participating in another investigative interventional cardiovascular device or drug study. * patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or stainless steel, or a sensitivity to contrast dye. * women of child bearing potential. * patient has other medical condition that may cause non-compliance with the protocol, confound the results, or is associated with limited life expectancy. * patient has been diagnosed with a myocardial infarction within 72 hours prior to procedure.

Keywords: coronary artery stent drug eluting patency restenosis
unity 3: a japanese phase 3 study of a daclatasvir/asunaprevir/bms-791325 in subjects with genotype 1 chronic hepatitis c

Conditions: Hepatitis C Virus Infection

Summary: the purpose of this study is to demonstrate that the proportion of treatment-naive non-cirrhotic subjects with genotype (gt)-1b treated with daclatasvir (dcv)/asunaprevir (asv)/bms-791325 who achieve sustained virologic response (svr12), defined as hepatitis c virus (hcv) rna \< loq target detected or target not detected (loq td/tnd) at follow-up week 12, is significantly higher than svr12 of current standard of care (soc).

limit of quantitation (loq) ribonucleic acid (rna) end of treatment (eot) triple direct acting antivirals (3daa)

Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * males and females, ≥ 20 years of age * subjects chronically infected with hcv gt-1 * hcv rna viral load of ≥ 100,000 iu/ml exclusion criteria: * hepatocellular carcinoma * co-infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv) * severe or uncontrollable complication
safety evaluation of a q-fever vaccine, ndbr 105

Conditions: Q Fever

Summary: the purpose of this study is to evaluate the safety of q fever vaccine, ndbr 105, and collect data on incidence of occupational q fever infection in at risk personnel.

study objectives: 1. continue to collect and assess safety data on q fever vaccine, phase i, inactivated, freeze-dried, ndbr 105, and 2) provide vaccine that potentially protects personnel at risk for occupational exposure to q fever and collect data on incidence of occupational q fever infection (subclinical and clinical) in immunized personnel.

Eligibility criteria:
inclusion criteria: * at least 18 years old, or if on active military duty, 17 years old. * females of childbearing potential must agree to have a urine pregnancy test on the same day before receipt of skin test antigen and vaccine. (exception: documented hysterectomy or \> three years of menopause.) the results must be negative. * volunteer must be actively enrolled in the sip * volunteer must be considered at risk for exposure to c. burnetii. * volunteer must sign and date the approved icd and hipaa authorization. * volunteer must have an up-to-date (within one year) medical history, physical examination, and laboratory tests on their charts and be medically cleared for participation by an investigator. examinations or tests may be repeated within one year at the discretion of the enrolling physician. * volunteer must be willing to return for all follow-up visits. * volunteer must agree to report any aes which may or may not be associated with administration of the test article for at least 28 days after vaccination. all saes and uaes will be reported for the duration of the volunteer's participation in the study (one year). exclusion criteria: * prior history of q fever disease or vaccination. * clinically significant abnormal lab results including evidence of hepatitis c, hepatitis b carrier state, or elevated liver function tests (two times the normal range or at the discretion of the pi). * personal history of an immunodeficiency or current treatment with an immunosuppressive medication or autoimmune disease. * confirmed hiv infection. * heart valve disease: murmur with abnormal echocardiogram (if murmur is detected on examination, volunteer will be referred to cardiologist to rule out pathology.) * positive pregnancy test or lactating female (females must agree to not become pregnant for three months after vaccination.) * any known allergies to components of the vaccine. * administration of another inactivated vaccine within 7 days or a live or ind vaccine within 28 days of q fever vaccination. * any unresolved ae resulting from a previous immunization.

Keywords: coxiella burnetti, bacterial infections, rickettsia, hepatits, endocarditis
contrast nephropathy in type 2 diabetes

Conditions: Kidney Function Affection Upon Exposure to Radiocontrast; Diabetes; Microalbuminuria

Summary: to study the effect of radiocontrast material on kidney functions in diabetics with microalbuminuria

study design: this study will be an observational prospective cohort study. study population: diabetics undergoing any intervention using radiocontrast material for any medical indication in fayoum universiy hospital will be selected. there will be two arms of the study,each arm will contain 20 patients first arm diabetics on linagelptin, second arm diabetics on other dpp4 inhibitors. data collection: patients will be subjected to; full clinical examination,waist hip ratio assessment,bmi assessment fasting blood glucose,serum uric acid, urine acr, egfr will be done before and after the investigation.

Eligibility criteria:
inclusion criteria: * diabetics on dpp 4 inhibitor treatment exclusion criteria: * diabetics on insulin
chinese multi-provincial cohort study-beijing project

Conditions: Cardiovascular Diseases; Cardiovascular Risk Factor; Aging Problems; Smell Disorder; Sleep

Summary: the chinese multi-provincial cohort study (cmcs)-beijing project is a sub-study in cmcs participants from beijing, which intended to investigate the progression and determinants of atherosclerosis and aging related health problems through repeat examinations. exam 0 to exam 3 have been conducted during 1992 to 2012. exam 4 is scheduled in 2020.


Eligibility criteria:
inclusion criteria: * participants from cmcs-beijing * sign the informed consent exclusion criteria: * participanting in clinical trials
effects of sugar-free products with added sweeteners on glycemic responses

Conditions: Potential Abnormality of Glucose Tolerance; Appetitive Behavior

Summary: this study investigated the effects of three commonly used sugar-free snacks with added sweeteners on glycemic responses

this study aimed at 1. to determine the glycemic index and glycemic load of three sugar-free products with added sweeteners: apricot jam, cranberry cereal bar, and cocoa drink, and 2. to investigate the effects of these products on the postprandial glycemic response in healthy subjects

Eligibility criteria:
inclusion criteria: * healthy * non-smoking * non-diabetic men and women * body mass index (bmi) between 18 and 29.9 kg/m2 exclusion criteria: * severe chronic disease (e.g. coronary heart disease, diabetes mellitus,kidney or liver conditions, endocrine conditions) * gastrointestinal disorders * pregnancy * lactation * competitive sports * alcohol * drug dependency

Keywords: blood glucose glycemic index cereal bar jam cocoa
sacubitril/valsartan in heart failure with reduced ejection fraction patients: a real world study in india

Conditions: Heart Failure

Summary: this was a non-interventional, retrospective emr analysis of longitudinal prescriptions in india for a period of 1.5 years. demographic profile of patients with heart failure with reduced ejection fraction on sacubitril/valsartan was recorded.

index date was date of 1st prescription of sacubitril/valsartan. dose titration of sacubitril/valsartan was assessed for a period of 6 months post index date.

Eligibility criteria:
inclusion criteria: * patients ≥18 years with a diagnosis of hfref as mentioned in database or heart failure with a recording of lvef \<40% at or before the index date * a prescription of sacubitril/valsartan exclusion criteria: * diagnosis of hf specified as preserved/mid-range ejection fraction

Keywords: heart failure with reduced ejection fraction hfref india sacubitril valsartan electronic medical records emrs retrospective rwe
validation of a new hand held light emitting diode device for the determination of minimal erythema dose (med)

Conditions: Phototherapy

Summary: the purpose of this study is to validate a new hand held light emitting diode (led) device for the measurement of minimal erythema dose (med) for narrow band ultraviolet b (uvb) radiation by comparing to the traditional approach of measurement of the minimal erythema dose.


Eligibility criteria:
inclusion criteria: 1. age greater than 18 years. exclusion criteria: 1. pregnancy 2. lactation 3. history of photosensitivity disorder 4. photosensitizing medications 5. personal history of melanoma or non-melanoma skin cancer. 6. skin disease on the back

Keywords: phototherapy light emitting diode minimal erythema dose narrowband uvb
structural problems in brainstem and cervical spine cord in me/cfs

Conditions: Chronic Fatigue Syndrome

Summary: a case control study on patients with me/cfs and healthy controls on prevalence of cervical obstructions, cerebro spinal fluid (csf) pressure and laboratory findings.

50 patients and 50 healthy controls will undergo clinical exams and blood test of inflammatory and other findings as well as magnetic resonance imaging (mri) with spectroscopy. the patients will undergo csf -sampling and measurements of csf pressure.

Eligibility criteria:
inclusion criteria: diagnose myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) according to canada consensus criteria from 2003 exclusion criteria: bleeding abnormality contraindication to magnetic resonance imaging mri pregnancy
optimised recovery with accelerated nutrition and gi enhancement

Conditions: Colorectal Liver Metastases

Summary: factors which delay recovery following uncomplicated abdominal surgery include uncontrolled pain, intolerance of diet and poor mobility. enhanced recovery after surgery (eras) programmes are perioperative care pathways that address systematically these issues (i.e. improved dynamic pain relief, optimised nutritional care and enforced mobilisation) to promote a faster recovery and a shorter stay. the key treatments that improve outcome within an eras programme are not known. moreover there are few acceptable, objective endpoints to assess key outcome variables such as return of gi function. this randomised trial will assess the potential synergy between early recovery of gi function (laxation) and early postoperative oral nutritional support(with associated preoperative preconditioning using carbohydrate/fluid loading). the main overall outcome targets being improved recovery of gastrointestinal function, postoperative nutritional status and physical function. it will validate the use of a novel, objective technique to measure gastric motility (surrogate for gi function). such refinement of eras should result in shorter hospital stay and better use of limited health care resource.


Eligibility criteria:
inclusion criteria: * patients undergoing hepatic resection for benign or malignant conditions * able to understand the nature of the study and what will be required of them. * men and non-pregnant, non-lactating women * bmi 18 - 30 exclusion criteria: * inability to give written, informed consent * patients with dementia or neurological impairment * patients with pre-existing condition limiting mobility * planned bile duct excision * repeat or staged procedures * central extended resections * underlying cirrhotic liver disease * jaundice (bilirubin \> 50 μmol/l)

Keywords: perioperative recovery nutrition enhanced laxative